Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
The firm said it saw a robust contribution in the first half of the year from its Dharmacon business and noted that it increased its reach into the US market.
The international team then used the approach to show that appropriate guide RNA design can reduce off-target effects of editing in mouse livers.
The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.
A new study shows that DNA targets bound by nucleosomes are cleaved less efficiently than targets lacking nucleosomes, which could inform target selection.
The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.
In Science this week: common metastatic driver genes, inhibitors of CRISPR, and more.
These Cas inhibitors — published in two studies — inhibit the activity of several Type V-A and Type I-C CRISPR systems, including several Cas12a orthologs.
The Associated Press reports on early, potentially promising results from a gene-editing trial.
Solana, founded in 2017 by former Illumina employees, has launched hundreds of products, including DNA sequencing solutions.
In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."
Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.